188 related articles for article (PubMed ID: 38311769)
21. Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer.
Chitapanarux I; Tharavichitkul E; Kamnerdsupaphon P; Pukanhapan N; Vongtama R
J Radiat Res; 2013 Nov; 54(6):1110-7. PubMed ID: 23740894
[TBL] [Abstract][Full Text] [Related]
22. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
[TBL] [Abstract][Full Text] [Related]
25. The superselective intra-arterial infusion of cisplatin and concomitant radiotherapy (RADPLAT) is effective for metastatic lymph nodes in head and neck squamous cell carcinoma.
Kano S; Suzuki T; Yoshida D; Tsushima N; Hamada S; Yasuda K; Uchinami Y; Aoyama H; Homma A
Int J Clin Oncol; 2023 Sep; 28(9):1121-1128. PubMed ID: 37289379
[TBL] [Abstract][Full Text] [Related]
26. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Ghi MG; Paccagnella A; Ferrari D; Foa P; Alterio D; Codecà C; Nolè F; Verri E; Orecchia R; Morelli F; Parisi S; Mastromauro C; Mione CA; Rossetto C; Polsinelli M; Koussis H; Loreggian L; Bonetti A; Campostrini F; Azzarello G; D'Ambrosio C; Bertoni F; Casanova C; Emiliani E; Guaraldi M; Bunkheila F; Bidoli P; Niespolo RM; Gava A; Massa E; Frattegiani A; Valduga F; Pieri G; Cipani T; Da Corte D; Chiappa F; Rulli E;
Ann Oncol; 2017 Sep; 28(9):2206-2212. PubMed ID: 28911070
[TBL] [Abstract][Full Text] [Related]
27. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.
Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516
[TBL] [Abstract][Full Text] [Related]
28. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 expression and prognosis in definitive radiotherapy patients with neuroendocrine cervical carcinoma.
Li H; Li X; Yang M; Su H; Zhang J; Hu C; Sun Y; Hu D; Chen L
J Clin Transl Res; 2023 Aug; 9(4):272-281. PubMed ID: 37593242
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study.
Wang K; Yi J; Huang X; Qu Y; Luo J; Xiao J; Zhang S; Tang Y; Liu W; Xu G; Gao L; Xu Z; Liu S; Wang X
Radiat Oncol; 2019 Dec; 14(1):225. PubMed ID: 31831042
[TBL] [Abstract][Full Text] [Related]
31. Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas.
Bohlen M; Busch C-; Sehner S; Forterre F; Bier J; Berliner C; Bußmann L; Münscher A
Eur Arch Otorhinolaryngol; 2019 Apr; 276(4):1183-1189. PubMed ID: 30725209
[TBL] [Abstract][Full Text] [Related]
32. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
[TBL] [Abstract][Full Text] [Related]
33. Tumor volume delineation in head and neck cancer with 18-fluor-fluorodeoxiglucose positron emission tomography: adaptive thresholding method applied to primary tumors and metastatic lymph nodes.
Perez-Romasanta LA; Bellon-Guardia M; Torres-Donaire J; Lozano-Martin E; Sanz-Martin M; Velasco-Jimenez J
Clin Transl Oncol; 2013 Apr; 15(4):283-93. PubMed ID: 22865325
[TBL] [Abstract][Full Text] [Related]
34. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: A randomized, multicenter, phase II clinical trial.
Liu Y; Zheng Z; Li M; Zhang Y; Zhao F; Gong H; Lin H; Huang W; Chen X; Xu Z; Li X; Liu W; Cui Y; Zheng A; Li B
Int J Cancer; 2022 Aug; 151(4):607-615. PubMed ID: 35419831
[TBL] [Abstract][Full Text] [Related]
35. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Chen J; Yin W; Yao H; Gu W
Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
[TBL] [Abstract][Full Text] [Related]
36. Lymph node ratio as a prognostic factor in head and neck cancer patients.
Chen CC; Lin JC; Chen KW
Radiat Oncol; 2015 Aug; 10():181. PubMed ID: 26302761
[TBL] [Abstract][Full Text] [Related]
37. Can adaptive threshold-based metabolic tumor volume (MTV) and lean body mass corrected standard uptake value (SUL) predict prognosis in head and neck cancer patients treated with definitive radiotherapy/chemoradiotherapy?
Akagunduz OO; Savas R; Yalman D; Kocacelebi K; Esassolak M
Nucl Med Biol; 2015 Nov; 42(11):899-904. PubMed ID: 26275933
[TBL] [Abstract][Full Text] [Related]
38. Lymph node ratio as a prognostic factor for survival in patients with head and neck squamous cell carcinoma.
Sano D; Yabuki K; Takahashi H; Arai Y; Chiba Y; Tanabe T; Nishimura G; Oridate N
Auris Nasus Larynx; 2018 Aug; 45(4):846-853. PubMed ID: 29203318
[TBL] [Abstract][Full Text] [Related]
39. Use of
Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
[No Abstract] [Full Text] [Related]
40. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
